Drug intelligence / Profile preview

iMBP-AD-500

Development stage: Unknown
Lead developer: iMetabolic Biopharma

Overview

iMBP-AD-500 is an investigational, computationally engineered biological drug candidate developed by iMetabolic Biopharma Corporation for the treatment of Alzheimer’s disease and mild cognitive impairment. Designed using the company’s proprietary iPlatform technology, it targets a novel, undisclosed mechanism that has not previously been addressed in Alzheimer’s therapy. The drug aims to simultaneously modulate lipid metabolism, reduce neuroinflammation, and inhibit abnormal neuronal protein (plaque) deposition—three key pathological features implicated in Alzheimer’s disease progression. Additionally, it is being developed to enhance blood-brain barrier transport for improved central nervous system delivery compared to current therapies[1][5][2].

Brand names: iMBP-AD-500iMBP-AD500iMBP-AD 500
Other names: iMBP-AD-500iMBP-AD500iMBP-AD 500

Beyond the preview

Go deeper on iMBP-AD-500.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on iMBP-AD-500.

Explore the full profile